Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
12 drugs in development
By Therapeutic Area
top 6
R&D Momentum
87/100
Pipeline Velocity
60/100
Trial Completion Rate
78/100
Pipeline Concentration
30/100
Pipeline Freshness
59/100
Strategic Signals
Activity
Last 14 days
METabolic MODulation to Enhance Insulin Sensitivity and Mitochondrial Function in Type 1 Diabetes (MetMod-T1D)
Utilizing Contrast-enhanced Ultrasound (CEUS) to Assess Critically Hypo Perfused Spinal Cord Tissue After Injury
A Multicenter Study PRECISE-HL: Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation in Advanced Hodgkin Lymphoma
APOE Genotype Effects on Triglycerides and Blood Flow in the Human Brain
Comparative Assessment of Neuromuscular Blockade Monitors
A Phase 2 Study of Biomarker-Modulated PSMA Theranostics
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)